Delivery Order SPE2DB20D3103-SPE2DB25FN7B7

Award Date 5/6/25
Potential Completion Date 5/7/25
Potential Value $5.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,996.66 firm-fixed-price delivery order is for the supply of Amox-Clav 875-125 mg tablets, a common antibiotic medication. The contract has a period of performance through May 6, 2025 and does not utilize a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a substantial...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,668.84 delivery order contract is for the procurement of AMOX-CLAV 875-125 MG TABLET 20S, a pharmaceutical product. The contract has a firm fixed price pricing type and a completion date of May 12, 2023. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,767.98, is a Firm Fixed Price Delivery Order for the supply of AMOX-CLAV 875-125 MG TABLET UD 100S. The contract has a completion date of March 25, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award is for $1,891.59 and was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of AMOX-CLAV 875-125 MG TABLET 100S, a type of antibiotic medication, and has an ultimate completion date of March 25, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. Amerisourcebergen holds a significant $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,543.50 firm fixed-price delivery order is for the supply of 4565751440 AMOX-CLAV 500-125 MG TABLET 20S. The contract has a completion date of September 11, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order valued at $9,849.54 for the supply of AMOX-CLAV 875-125 MG TABLET UD 100S, a generic pharmaceutical product. The contract has an ultimate completion date of March 20, 2025 and is a Firm Fixed Price contract. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,060.03 firm fixed-price delivery order is for AMOX-CLAV 250-125 MG TABLET 30S, a generic pharmaceutical product. The award is not designated under any set-aside program. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $1,265.87 delivery order is for the supply of Amox-Clav 875-125 mg tablets, a prescription medication. The contract has a firm-fixed price and an ultimate completion date of December 15, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,088.28 firm fixed-price delivery order is for AMOX-CLAV ER 1,000-62.5 MG TAB UU 28S, a pharmaceutical product, and has a completion date of December 19, 2023. The award is not associated with a set-aside designation. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $1,511.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4560843903 AMOX-CLAV 875-125 MG TABLET 20S, a generic pharmaceutical product. The contract type is a Delivery Order with a Firm Fixed Price pricing structure, and the ultimate completion date is May 8, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FN7B7
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,077.90 firm fixed-price delivery order is for the supply of AMOX-CLAV 875-125 MG TABLET 100S, a pharmaceutical product. The contract has an ultimate completion date of May 7, 2025 and is not designated as a set-aside.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00. This prime contract, designated as SPE2DX, provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. The IDC enables the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 8/10/25, 1:20 AM